Melissa Fiorini, M.D., clinical director of St. Peter’s Health Partners’ monoclonal antibody infusion clinic, was interviewed by WTEN/News10 about the COVID-19 treatment, including a new antibody recently approved by the FDA.
From the story:
More than 500 patients have passed through St. Peter’s Health Partners’ (SPHP) monoclonal antibody infusion clinic to receive treatment for COVID-19. An additional antibody was approved on an emergency basis by the U.S. Food and Drug Administration (FDA) Tuesday.
When available, etesevimab will be given in conjunction with Eli Lilly and Company’s bamlanivimab, said Melissa Fiorini, M.D., clinical director at SPHP monoclonal antibody infusion clinic. She said the combination antibody treatment will better treat variant strains of COVID-19.
“I think it becomes more of an issue when we start to see the variant forms of the virus because if you have two different antibodies, working on two different sites, then you’re less likely to have the variants be able to escape,” said Dr. Fiorini.
Click here to read the full report.